Search Results for: Clinical Roundup
-
Clinic Roundup
In the trial, aldoxorubicin showed prolonged clinical activity, including partial tumor response, in two subjects with small-cell lung cancer who had failed other therapies...Promedior Inc., of Malvern, Pa., presented data from a clinical study of PRM-151 at the American Thoracic Society Conference in PhiladelphiaBioWorld Today | Thursday, May 23, 2013 -
Pharma: Clinic Roundup
SONAR is a multinational, double-blind, placebo-controlled clinical study that is expected to enroll more than 4,000 patients with diabetic nephropathyBioWorld Today | Tuesday, May 21, 2013 -
Tokai Adds $35.5M in Series E, Preps for Phase III CRPC Trials
In addition to Zytiga and Xtandi, the FDA approved Wednesday Xofigo (radium Ra 223 dichloride), an alpha particle-emitting radioactive therapeutic agent from Algeta ASA and partner Bayer AG that demonstrated in clinical studies an overall survival benefit with antitumor effects on bone metastases...Receptos will use the proceeds to support clinical work in multiple sclerosis, inflammatory bowel disease and allergic/immune-mediate disorders. (See BioWorld Today, May 10, 2013By Jennifer Boggs | BioWorld Today | Thursday, May 16, 2013 -
Clinic Roundup
These data led to Eleven's Phase Ib clinical study of EBI-005 in subjects with dry eye disease, with top-line data from the Phase Ib study expected in the second half of 2013BioWorld Today | Thursday, May 9, 2013 -
ECCMID Roundup
In addition to the detailed efficacy and safety results of the ESTABLISH-2 study, which build upon the top-line results previously announced, Trius presented the results of a drug interaction clinical study demonstrating that tedizolid phosphate did not increase blood pressure when used in conjunction with vasoconstrictor drugs such as decongestants...The results of a separate clinical cardiovascular safety study showed that tedizolid was not associated with heart beat abnormalities at up to sixBioWorld Today | Tuesday, April 30, 2013 -
Clinic Roundup
Regentis raised $10 million last year in a Series C financing to support clinical studies and commercial launch of GelrinC in Europe. (See BioWorld Today, May 15, 2012BioWorld Today | Thursday, April 11, 2013 -
Clinic Roundup
RP5063 also showed efficacy in the Clinical Global Impression Severity Scale and was well tolerated...Viralytics Ltd., of Sydney, Australia, said it finalized the clinical study report on the Phase I evaluation of Cavatak, administered intravenously to late-stage melanoma, prostate, breast or colorectal cancer patients, with results showing that the oncolytic virus-based drug candidate was well tolerated, with some evidence of stable disease despite most patients only receiving a single doseBioWorld Today | Wednesday, April 10, 2013 -
AAN Roundup
BrainStorm Cell Therapeutics Inc., of New York, reported some of the final results from a clinical study evaluating its NurOwn technology in 12 amyotrophic lateral sclerosis (ALS) patients...The Phase I/II trial showed a significantly slower decline in overall clinical and respiratory function, as measured by the ALS functional rating score (ALSFRS-R) and forced vital capacity (FVC) score, respectively, in the six patients who received an intrathecal injection of the cells in the six monthsBioWorld Today | Friday, March 22, 2013 -
Clinic Roundup
The NX03-0040 prostate cancer clinical study of 150 men is testing low (2.5 mg) and high (15 mg) single doses of NX-1207 for the effect to eradicate or shrink low-grade localized prostate cancer tumorsBioWorld Today | Wednesday, March 20, 2013 -
$7M Series B Puts Investor Skin in Game for Brickell
The company is planning to begin clinical studies in the first half of 2014By Catherine Shaffer | BioWorld Today | Wednesday, February 27, 2013 -
White House: Give the Public its Money's Worth
Published in Tuesday's Federal Register, the final guidance clarifies the terms "due diligence," "covered clinical study" and "material support...and explains the FDA's review of clinical investigator financial disclosure information.By Mari Serebrov | BioWorld Today | Tuesday, February 26, 2013 -
Pharma: Clinic Roundup
Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said pinoxacin hydrochloride received approval for clinical studies from the State Food and Drug AdministrationBioWorld Today | Monday, February 25, 2013 -
Clinic Roundup
Amicus Therapeutics Inc., of Cranbury, N.J., reported positive results from clinical and preclinical studies of the pharmacological chaperone AT2220 (duvoglustat HCl) in combination with ERT for Pompe disease at the Lysosomal Disease Network World Symposium...Based on those results, the company plans to initiate a repeat-dose clinical study in the third quarter of 2013 to evaluate an intravenous formulation of AT2220 co-administered with Myozyme/LumizymeBioWorld Today | Friday, February 15, 2013 -
Clinic Roundup
Critical Pharmaceuticals Ltd., of Nottingham, UK, completed a second clinical study of CP024, a growth hormone nasal spray in development for growth disorders in children and adultsBioWorld Today | Wednesday, February 13, 2013 -
Financings Roundup
The net proceeds will be used for working capital and general corporate purposes, including the continuation of the Abili-T clinical study, Opexa's ongoing Phase IIb trial of Tcelna in secondary progressive multiple sclerosis patientsBioWorld Today | Friday, February 8, 2013 -
GAO: Agencies Earn Poor Grades in Transparency
Thus, "Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling" is specifically for use in exploratory and observational studies that are intended to generate genomic hypotheses that will be tested in later confirmatory trialsBy Mari Serebrov | BioWorld Today | Monday, January 28, 2013 -
Clinic Roundup
Sirtex Medical Ltd., of New South Wales, Australia, reported results from an analysis of 548 patients in a clinical study testing Selective Internal Radiation Therapy (SIRT) with SIR-Spheres microspheres in patients with metastatic colorectal cancer...Those data were presented at the American Society of Clinical Oncology's 2013 Gastrointestinal Cancers Symposium in San FranciscoBioWorld Today | Friday, January 25, 2013 -
Clinic Roundup
Those data completed the pivotal pharmacokinetic and clinical program for BNX, which BDSI said will enable a new drug application submission in mid-2013...Sihuan Pharmaceutical Holdings Group Ltd., of Hong Kong, said it received approval for clinical studies from Chinese regulators to test Benapenem, a carbapenem drug in the class of broad-spectrum beta-lactam antibiotics, with a Phase I program set to start in the first half of this yearBioWorld Today | Wednesday, January 23, 2013 -
Clinic Roundup
CrystalGenomics Inc., of Seoul, South Korea, said it received a draft of the clinical study report from the recently completed Phase IIa study of CG400549, an antibiotic candidate for methicillin-resistant Staphylococcus aureus (MRSA...The complete clinical study report for the interim analysis would be supplied to the FDA during the review within 60 days of the resubmissionBioWorld Today | Tuesday, January 8, 2013 -
Clinic Roundup
Durata said the secondary endpoint of clinical success at the end of treatment – the expected primary endpoint for regulatory review in Europe – also was met...NovaBay Pharmaceuticals Inc., of Emeryville, Calif., said the first patients have been enrolled in India into its global Phase IIb BAYnovation clinical study, investigating NVC-422 ophthalmic solution as a treatment of adenoviral conjunctivitis, a highly contagious form of "pink eye" for which there is an unmet ocular medical needBioWorld Today | Monday, January 7, 2013
Category
Current Filters
- xclinical studies
Related Keywords
Categories
- x BioWorld Today (357)
- x BioWorld International (4)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.